RS67478B1 - Dozni režim migalastata sa poboljšanom farmakokinetikom - Google Patents
Dozni režim migalastata sa poboljšanom farmakokinetikomInfo
- Publication number
- RS67478B1 RS67478B1 RS20251212A RSP20251212A RS67478B1 RS 67478 B1 RS67478 B1 RS 67478B1 RS 20251212 A RS20251212 A RS 20251212A RS P20251212 A RSP20251212 A RS P20251212A RS 67478 B1 RS67478 B1 RS 67478B1
- Authority
- RS
- Serbia
- Prior art keywords
- migalastat
- salt
- patient
- caffeine
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263432235P | 2022-12-13 | 2022-12-13 | |
| US18/315,928 US20240197706A1 (en) | 2022-12-13 | 2023-05-11 | Methods of improving the pharmacokinetics of migalastat |
| EP23176366.5A EP4385509B1 (en) | 2022-12-13 | 2023-05-31 | Migalastat dosage regimen having improved pharmacokinetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS67478B1 true RS67478B1 (sr) | 2025-12-31 |
Family
ID=86646511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20251212A RS67478B1 (sr) | 2022-12-13 | 2023-05-31 | Dozni režim migalastata sa poboljšanom farmakokinetikom |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20240197706A1 (https=) |
| EP (2) | EP4667050A3 (https=) |
| JP (2) | JP7757345B2 (https=) |
| KR (1) | KR20240094973A (https=) |
| AU (1) | AU2023396459A1 (https=) |
| CA (1) | CA3201512A1 (https=) |
| CL (1) | CL2025001743A1 (https=) |
| CO (1) | CO2025009079A2 (https=) |
| DE (1) | DE202023003007U1 (https=) |
| DK (1) | DK4385509T3 (https=) |
| ES (1) | ES3055214T3 (https=) |
| FI (1) | FI4385509T3 (https=) |
| HR (1) | HRP20251472T1 (https=) |
| IL (1) | IL321404A (https=) |
| LT (1) | LT4385509T (https=) |
| MX (1) | MX2025006897A (https=) |
| PL (1) | PL4385509T3 (https=) |
| PT (1) | PT4385509T (https=) |
| RS (1) | RS67478B1 (https=) |
| SI (1) | SI4385509T1 (https=) |
| SM (1) | SMT202500453T1 (https=) |
| TW (1) | TW202423436A (https=) |
| WO (1) | WO2024129220A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| AU2008232614A1 (en) | 2007-03-30 | 2008-10-09 | Amicus Therapeutics, Inc. | Method for the treatment of Fabry disease using pharmacological chaperones |
| US9999618B2 (en) * | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| SI3470077T1 (sl) | 2008-02-12 | 2020-12-31 | Amicus Therapeutics, Inc. | Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem |
| CN103974619B (zh) * | 2011-03-11 | 2017-02-15 | 阿米库斯治疗学公司 | 治疗法布里病的给药方案 |
| EP4426846A4 (en) * | 2021-11-03 | 2025-11-05 | Sangamo Therapeutics Inc | METHODS OF USING VIRAL VECTOR CONSTRUCTIONS FOR THE TREATMENT OF FABRY DISEASE |
-
2023
- 2023-05-11 US US18/315,928 patent/US20240197706A1/en active Pending
- 2023-05-31 SM SM20250453T patent/SMT202500453T1/it unknown
- 2023-05-31 IL IL321404A patent/IL321404A/en unknown
- 2023-05-31 WO PCT/US2023/067656 patent/WO2024129220A1/en not_active Ceased
- 2023-05-31 SI SI202330057T patent/SI4385509T1/sl unknown
- 2023-05-31 ES ES23176366T patent/ES3055214T3/es active Active
- 2023-05-31 EP EP25199386.1A patent/EP4667050A3/en active Pending
- 2023-05-31 HR HRP20251472TT patent/HRP20251472T1/hr unknown
- 2023-05-31 LT LTEP23176366.5T patent/LT4385509T/lt unknown
- 2023-05-31 DK DK23176366.5T patent/DK4385509T3/da active
- 2023-05-31 PL PL23176366.5T patent/PL4385509T3/pl unknown
- 2023-05-31 TW TW112120343A patent/TW202423436A/zh unknown
- 2023-05-31 RS RS20251212A patent/RS67478B1/sr unknown
- 2023-05-31 AU AU2023396459A patent/AU2023396459A1/en active Pending
- 2023-05-31 EP EP23176366.5A patent/EP4385509B1/en active Active
- 2023-05-31 CA CA3201512A patent/CA3201512A1/en active Pending
- 2023-05-31 FI FIEP23176366.5T patent/FI4385509T3/fi active
- 2023-05-31 KR KR1020230070371A patent/KR20240094973A/ko not_active Ceased
- 2023-05-31 JP JP2023090210A patent/JP7757345B2/ja active Active
- 2023-05-31 DE DE202023003007.2U patent/DE202023003007U1/de active Active
- 2023-05-31 PT PT231763665T patent/PT4385509T/pt unknown
-
2025
- 2025-06-12 CL CL2025001743A patent/CL2025001743A1/es unknown
- 2025-06-12 MX MX2025006897A patent/MX2025006897A/es unknown
- 2025-07-03 CO CONC2025/0009079A patent/CO2025009079A2/es unknown
- 2025-10-08 JP JP2025169972A patent/JP2026031546A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SI4385509T1 (sl) | 2026-01-30 |
| PL4385509T3 (pl) | 2026-02-16 |
| WO2024129220A1 (en) | 2024-06-20 |
| FI4385509T3 (fi) | 2025-12-05 |
| DK4385509T3 (da) | 2025-12-08 |
| HRP20251472T1 (hr) | 2026-01-02 |
| MX2025006897A (es) | 2025-07-01 |
| LT4385509T (lt) | 2025-12-29 |
| EP4667050A3 (en) | 2026-03-25 |
| EP4385509B1 (en) | 2025-09-03 |
| KR20240094973A (ko) | 2024-06-25 |
| DE202023003007U1 (de) | 2025-07-21 |
| SMT202500453T1 (it) | 2026-01-12 |
| EP4385509A1 (en) | 2024-06-19 |
| JP7757345B2 (ja) | 2025-10-21 |
| PT4385509T (pt) | 2025-11-25 |
| TW202423436A (zh) | 2024-06-16 |
| JP2024084670A (ja) | 2024-06-25 |
| US20240197706A1 (en) | 2024-06-20 |
| CA3201512A1 (en) | 2024-06-13 |
| JP2026031546A (ja) | 2026-02-24 |
| CO2025009079A2 (es) | 2025-09-29 |
| IL321404A (en) | 2025-08-01 |
| EP4667050A2 (en) | 2025-12-24 |
| AU2023396459A1 (en) | 2025-06-26 |
| ES3055214T3 (en) | 2026-02-10 |
| CL2025001743A1 (es) | 2025-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4324521B1 (en) | Migalastat for use in the treatment of fabry disease in ert-naive and ert-experienced patients | |
| US20240277687A1 (en) | Methods of treating fabry disease in patients having a mutation in the gla gene | |
| JP7677910B2 (ja) | 腎機能障害を有する患者のファブリー病を治療する方法 | |
| RS66515B1 (sr) | Metode unapređenja i/ili stabilizacije srčanih funkcija kod pacijenata sa fabrijevom bolešću | |
| EP4114390B1 (en) | Methods of treating fabry disease in patients having a mutation in the gla gene | |
| RS66410B1 (sr) | Upotreba migalostata u smanjenju rizika od cerebrovaskularnog događaja kod pacijenata sa fabrijevom bolešću | |
| RS67478B1 (sr) | Dozni režim migalastata sa poboljšanom farmakokinetikom | |
| EP4370120A1 (en) | Methods of treating fabry disease in pediatric patients | |
| HK40104441A (en) | Methods of treating fabry disease in patients having a mutation in the gla gene | |
| HK40105450A (en) | Methods of treating fabry disease in patients having a mutation in the gla gene | |
| HK40104069A (en) | Methods of treating fabry disease in patients having a mutation in the gla gene | |
| HK40104764A (en) | Methods of treating fabry disease in patients having a mutation in the gla gene | |
| HK40104071A (en) | Methods of treating fabry disease in patients having a mutation in the gla gene | |
| HK40057125B (en) | Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene | |
| HK40057125A (en) | Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene |